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Lactation is a state of rapid bone loss for milk production; however, the 
maternal bone undergoes a rapid remineralization after weaning. Sclerostin, 
encoded by the gene SOST, is exclusively secreted from osteocytes and has 
important regulator of bone remodeling by inhibiting Wingless and Int-1 (Wnt) 
signaling by binding to extracellular domain of low-density lipoprotein 
receptor-related protein 5/6 (LRP5/6). However, the role of sclerostin-Wnt 
signaling for controlling bone remodeling during lactation and weaning has not 
been studied. In this study, we hypothesized that sclerostin related with Wnt 
signaling would affect bone metabolism and microstructures during lactation 
and weaning, and pregnancy and lactation associated osteoporosis (PLO) would 
 
2 
be related with mutation of Wnt signaling pathway. We used whole-exome 
sequencing (WES) to reveal associations between genetic variants and PLO 
patients with multiple vertebral fractures. We also used dual energy X-ray 
absorptiometry (DXA), micro-computed tomography (µCT) to evaluate and 
compared the effect of sclerostin on bone mass and microarchitectures of wild 
type and DMP1-Sost transgenic mice, in which sclerostin is overexpressed by 
osteocyte. As a result, WES showed 8 out of 12 patients showed LRP5/6 
mutation encoding the extra-cellular signaling domain of LRP5/6, which 
sclerostin or Wnt signaling agonists bind to. In animal study, lactation 
significantly lead to decreased spine and femur bone mineral density (BMD) at 
1-week and 3-week of lactation; especially cortical microstructure 
(cross-sectional thickness and cross-sectional area) at mid-shaft femur were 
significantly deteriorated. At 2-week after weaning, incomplete recovery of 
femur BMD and cortical microstructure at mid-shaft femur in both wild and 
DMP1-Sost mice; however, spine BMD and trabecular microstructures at distal 
femur were recovered only in wild type mice, suggesting that 
sclerostin-overexpression would affect bone formation, especially in trabecular 
dominant bone compartment during weaning period. In conclusion, LRP5/6 
mutations related with Wnt pathway, would be one of the plausible risk factors 
of failure of maternal bone mineral adaptation to severe bone loss during 
lactation and weaning contributing to PLO. To activate Wnt signaling pathway 
during lactation and after weaning for compensation of bone loss, control of 
 
3 
sclerostin level by osteocytes would be important to maintain bone mineral 
metabolism.  
 ________________________________________________________ 
Key Words: Wnt signaling pathway, DMP1-hSOST transgenic mice, 
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I. INTRODUCTION 
Pregnancy and lactation are associated with a change of maternal bone and 
mineral metabolism1,2. To meet fetal and neonatal demands during pregnancy 
and lactation without requiring increased intakes of calcium, calcium inevitably 
comes from the maternal skeleton3. This results to deterioration of bone mass in 
the mother. Normally, after weaning, maternal skeleton undergoes to regain 
mineralization1 and lactational loss of bone density is completely reversed 
within one year in most women4-6. Rarely, a failure of maternal adaptations in 
mineral and skeletal homeostasis in a period of pregnancy, lactation, and 
weaning, could induce pregnancy- and lactation-associated osteoporosis (PLO), 
presented as vertebral compression fractures7-11. Since PLO is a rare condition, 
and there is no rationale to screen bone mineral density of young pregnant 
women during a peripartum period without previous fracture, to evaluate and 
find the etiology of PLO is very difficult12. 
 Lactation is a state of rapid bone loss for milk production. Bone turnover is 
markedly increased during lactation and causes net resorption13. To maintain the 
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bone homeostasis, bone resorption occurs by osteoclast-mediated bone 
resorption and osteocytic osteolysis14-17. Osteoclast-mediated bone resorption 
was mainly known as a mechanism by which bone is resorbed to release 
calcium during lactation; however, osteocytic osteolysis has been recently 
revealed as potential mechanism by which the mineral is mobilized from 
cortical bone, the potential for mineral bone suggesting important role of 
osteocyte in pregnancy. Osteocytes have been also revealed to have important 
role of actively removing mineralized tissue during and replacing it during the 
recovery period after weaning18-20. 
 Sclerostin, encoded by the gene SOST, is secreted in bone by mature 
osteocytes. Sclerostin binds to low-density lipoprotein receptor-related protein 
5/6 (LRP5/6), inhibiting osteoblastic bone formation by canonical Wnt pathway 
21. While there is no question that sclerostin has a central role in bone biology, 
the impact of sclerostin on bone metabolism during lactation and weaning has 
not been well studied yet. So, we hypothesized that sclerostin related to Wnt 
signaling is essential for maintaining maternal bone mass and 
microarchitectures in lactation and weaning 21.  
To demonstrate the relation of to Wnt signaling and sclerostin in pregnancy- 
and lactation – associated osteoporosis (PLO), we evaluated 1) the gene 
mutations related to Wnt signaling pathway in our PLO women by 
whole-exome sequencing; 2) the impact of sclerostin on bone density and 
microarchitecture during lactation and weaning periods by using DMP1-Sost 




II. MATERIALS AND METHODS 
1. Whole exome sequencing  
We enrolled 12 women who had vertebral fractures with pregnancy and 
lactation osteoporosis and analyzed whole exome sequencing (WES). WES was 
done by SureSelect v4+UTR (71Mbp region). Sequencing data was processed, 
ingle nucleotide polymorphism, indel were found by HaplotypeCaller. After 
quality control and filtering, variants on candidate PLO genes were screened. 
After processing the sequencing data, single nucleotide variations (SNV), short 
insertion or deletions (Indels) were discovered. Silent variants and coding 
non-silent variants were removed after quality control. We used candidate gene 
analysis. First, “Bone”, “bone mineral density” and “osteopo-” related 
gene-mutations based on human gene-mutation database (HGMD)22 were 
matched to our samples. Second, Osteoporosis, Wnt pathway, pregnancy related 
genes were chosen (Fig. 1).  
 






Figure 2. Study design 
 
DMP1-hSOST transgenic mice were generated by inserting the human Sost 
cDNA (I.M.A.G.E. clone ID 40009482, American Tissue Culture Collection, 
Manassas, VA, USA) downstream from a 12-kb DNA fragment containing 8 kb 
of the 50-flanking region, the first exon, the first intron, and 17 bp of exon 2 of 
the murine DMP1 gene and upstream from a 140-bp fragment containing the 
rabbit beta-globin polyadenylation sequence.23 Transgenic mice were produced 
by microinjection of purified DNA into pronuclei of C57BL/6 mice at the 
transgenic mouse core facility of the University of Arkansas for Medical 
Sciences. DMP1-Sost mice were born at the expected Mendelian frequency, 
were fertile, and exhibited normal size and weight 24.  
Ten-week-old DMP1-hSOST transgenic (TG) or wild type (WT) 
female mice were mated with wild C57BL6 (WT) male, and after female mice 
became pregnant, males were removed. After birth, lactating females were 
randomly assigned to three groups in both genotypes according to the time of 
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lactation or weaning; lactation day 7, day 21, and day 14 after weaning. After 
finishing lactation or weaning, mice were sacrificed (Fig 2). Age matched 
non-lactating control mice, of which pups were removed right after birth, were 
also maintained until each time point in both wild type and DMP1-hSOST 
transgenic mice; no-lactation until day 7, day 21, and day 35. All age-matched 
animals were ± 3 days of lactating animals. Mice were fed a diet containing 
0.81% calcium and 0.64% phosphorus (LabDiet, St. Louis, MO, USA) and 
water and were maintained on a 12-hour light/dark cycle.  
 
3. Dual-energy X-ray absorptiometry (DXA)  
Bone mineral density (BMD) was measured by DXA using an InAlyzer 
densitometer (Medikors, Korea). Mice were sacrificed and T12 to L3 vertebra 
and left femur were dissected, cleaned of soft tissue, fixed at 10 % formalin for 
3 weeks, and stored in 70% ethanol. The region of interest (ROI) for lumbar 
spine was L1, L2, and L3. Whole femur was measured for total femoral areal 
BMD.    
 
4. Microcomputed tomography (µCT) 
The microarchitecture of the left femur were analyzed by scanning at 1.5mm 
below the growth plate for trabecular bone, and at 4.5mm below the growth 






5. Serum biochemical parameters  
Blood sampled were collected at the facial vein, and centrifuged at 3000 relative 
centrifugal force (RCF). Serum sclerostin (R&D Systems, Minneapolis, MN, 
USA), the amino-terminal propeptide of type 1 procollagen (P1NP)(IDS, 
Boldon, U.K), cross-linked C-telopeptide (CTX) (IDS, Boldon, U.K) were 
measured with using enzyme-linked immunosorbent assays. 
 
6. Statistical analysis 
Statistical analyses were performed using SPSS 22.0 (PASW Statistic, SPSS, 
IBM, Chicago, IL, USA) and GraphPad Prism version 6.0 for Windows 
(GraphPad Software, La Jolla, CA, USA). Differences between two groups 
were tested by t-test were used. Spearman correlation test were used to analysis 
correlation tendency. Data are presented as mean ± SD or n (%). A P-value 
<0.05 was considered to be statistically significant
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III. RESULTS  
1. Whole-exome sequencing data of subjects in pregnancy and 
lactation osteoporosis (PLO) 
1-1. Clinical characteristics of 12 women  
All women had more than one vertebral compression fractures. Ten women 
were primiparas. The mean age and body mass index (BMI) of women were 
31.2 ± 2.7 years and 20.3 ± 2.1 kg/m2, respectively (Table 1). No subjects 
had a history of fractures before pregnancy, and 2 women had a family history 
of osteoporosis or vertebral fractures. The duration of lactation was 3 [2-3] 
months, documentation of fractures of all women by any imaging examination 
was within 3 months. Subjects had lower lumbar spine bone mineral density 
(BMD) (0.620 ± 0.181g/cm2, Z-score = -3.0 ± 0.7). 
1-2. Candidate PLO genes  
All variants type were all disease-associated polymorphism (DP) or 
disease-associated polymorphism with additional supporting functional 
evidence (DFP). Ten of twelve women have heterozygous or homozygous 
mutations of gene mutations enc                                                                        
oding receptor activator of nuclear factor ĸ B (RANK) (TNFRSF11A)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
25, osteoprotegerin (TNFRSF11B)26, a decoy receptor for RANK, calcitonin  
receptors (CALCR)27, PR domain zinc finger protein 2 (PRDM2)28,29, interacting 
with estrogen receptor alpha suggesting that bone resorption and mineral me         
tabolism are also importantly involved in PLO women (Table 2).  
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Table 1. Clinical characteristics of 12 patients 
  
ID Age  































1 30 ∙ 161 44.5 18.3 2 15 T8,10,L2,L3  4 0.704 -2.9 0.734 -0.2 0.784 -0.6 
2 29 ∙ 168 54 18.6 1 8 T9,11,12,L1  4 0.545 -4 0.488 -2.4 0.6 -2.2 
3 30 ∙ 159.3 42.7 17.2 1 3 L1,3,4,5  4 0.743 -2.8 0.517 -2.2 0.574 -2.3 








and mother ) 
164 53 20.4 1 2 T6,8,12,L1,3  5 0.641 -2.9 0.578 -1.5 0.712 -1.2 




158 53 21.2 1 0 T12,L2,4  3 0.576 -3.4 0.478 -2.5 0.564 -2.5 
9 33 ∙ 160 46 19.5 1 2 T5,T12  2 0.47 -4.6 0.491 -2.3 0.596 -2.2 
10 30 ∙ 156 50 20.8 1 3.3 T11,12,L1,2,5  5 0.849 -2.7 0.88 -1 0.839 -1.2 
11 27 ∙ 160 59 23.1 2 3 T2,T9,T11,L1,L2-5 8 0.175 -2.5 0.603 -1.3 0.797 -0.5 





  0.53 -1.65 0.637 -1.46 
BMI, body mass index; Fx, fracture; LS, lumbar spine; aBMD, areal bone mineral density; TH, total hip  
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Table 2. 23 known "bone","bone mineral density","osteoporo-" gene mutations in human gene mutation database (HGMD)  
























CD043415 BMD rs2308040 DFP 0.082 0.542 0.364       
 
          
 




CM1312606 BMD rs16861032 DP 0.085 0.208 0.097     
     







CM093421 Hip BMD rs1054627 DP 0.687 0.167 0.137 









CM1413823 BMD rs17013182 DP 0.118 0.042 0.161 
  
  








    







CM093420 Hip BMD rs1422795 DP 0.671 0.125 0.158 
 
  





CM093417 BMD rs6929137 DP 0.487 0.25 0.318 
   
  
  
    
  











CM127941 BMD rs2908004 DP 0.161 0.083 0.2 
 
  









rs2707466 DP 0.17 0.083 0.197 
 
  









rs3134295 DP 0.857 0.333 0.352 
 
    
 
  
   







rs3134296 DP 0.719 0.292 0.327 
 
    
 
  
   
  
 







rs3134253 DP 0.904 0.333 0.346 
 
    
 
  
   







rs2073618 DP 0.387 0.208 0.291   
 




CM094855 Low BMD rs3747532 DP 0.745 0.042 0.058   







rs41494349 DP 0.54 0.125 0.088 
    
  
   
















CM1312608 BMD rs2657879 DP 0.482 0.042 0.082 









rs5742915 DP 0.015 0.042 0.003 
   
  











rs1805034 DFP 0.976 0.333 0.33             
 




CM034611 Bone mass rs2273073 DFP 0.281 0.045 0.122                         






1-3. Candidate PLO-associated pathways  
 
We evaluated the genes related with Wnt signaling pathway, osteoporosis, bone, 
pregnancy, and lactation. LRP5/6 gene mutations were common parts of 
Wnt-signaling pathway, osteoporosis and bone (Fig. 3). Figure 4 showed the 
variants in LRP5/6 and SOSTDC1 gene. The arrows show the common, low, 
rare mutations in LRP5/6 and SOSTDC1 gene, all related with Wnt signal 
pathway important to induce bone formation. Compared to control group, LRP5 
mutations p.Gln89Arg in S05,S09,S10 and p.Ala1330Val in 
S01,S05,S06,S07,S09, S10 case were found as common variant (minor allele 
frequency (MAF) > 0.05). Low variants (0.01 < MAF < 0.05), p.Ser127Thr in 
LRP6 gene were found in S12. LRP5 mutations p.Arg701His, p.Tyr1082Cys, 
LRP6 mutations p.Ser61Gly, p.Val90Ile as rare variants (MAF < 0.01) were 
revealed in 3 samples (Fig. 4). Interestingly, SOSTDC1 mutation p.Leu50Phe 
was found in S03. SOSTDC1, also known as Wise gene, encodes secreted 
glycoproteins that antagonize WNT signaling by binding to LRP5, LRP6 or 
both. LRP5/6 mutations are located in β-propeller extracellular domain of 















 2. Effect of lactation  
2-1. Bone density and microarchitectures 
Both early and late lactation lowered the all spine and femur BMD at 1-week or 
3-week in lactating mice compared to age-matched non-lactating mice (Fig. 5). 
Lactation deteriorates trabecular and cortical bone loss at early and late lactation 
(Table 3-4). Among micro CT parameters, lower cross-sectional thickness, 




Figure 5. Effect of lactation at 1 and 3 week on BMD
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Table 3. Differences in femoral µCT phenotypes by lactation at 1-week 
 Wild type DMP1-Sost 
 
non-lactating 
group lactating group  
non-lactating 
group lactating group 
 
 
(n = 5) (n = 5) 
 
(n = 5) (n = 5) 
 
  Mean  SD Mean 
 
SD p-value Mean  SD Mean  SD p-value 
Distal femur 








TV, mm3 3.34  ± 0.14  2.96  ± 0.26  0.02  3.22  ± 0.30  2.86  ± 0.27  0.08  
BV, mm3 0.63  ± 0.19  0.60  ± 0.17  0.76  0.19  ± 0.18  0.13  ± 0.15  0.60  
BV/TV ,% 18.82  ± 5.35  20.04  ± 5.18  0.72  5.43  ± 4.65  4.22  ± 4.56  0.69  
Tb.Th, µm 71.69  ± 2.13  72.12  ± 5.13  0.87  73.31  ± 4.96  68.69  ± 3.23  0.12  
Tb.N,1/mm 2.62  ± 0.72  2.76  ± 0.59  0.75  0.77  ± 0.72  0.62  ± 0.68  0.74  
Tb.Sp, mm 0.27  ± 0.06  0.24  ± 0.03  0.42  0.83  ± 0.29  0.66  ± 0.28  0.39  
Conn.D,1/mm3 102.91  ± 41.83  111.32  ± 50.77  0.18  27.55  ± 20.69  15.10  ± 19.70  0.36  
Midshaft femur 
    
 
      
 
  
Cs.Th,mm 0.13  ± 0.01  0.17  ± 0.02  <0.01 0.14  ± 0.01  0.15  ± 0.01  0.05  
periosteal perimeter[mm] 4.73  ± 0.12  4.76  ± 0.09  0.67  4.80  ± 0.20  4.79  ± 0.12  0.96  
endosteal perimeter[mm] 4.09  ± 0.15  3.90  ± 0.09  0.04  4.15  ± 0.19  3.98  ± 0.15  0.16  
CSA, mm2 0.60  ± 0.02  0.74  ± 0.07  <0.01 0.63  ± 0.07  0.69  ± 0.04  0.17  
MMI, mm4 0.27  ± 0.02  0.32  ± 0.04  0.02  0.30  ± 0.05  0.31  ± 0.03  0.52  
Abbreviations: TV, tissue volume; BV, bone volume; BV/TV, percent bone volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, 
trabecular separation; Conn.D,connectivity density; Cs.Th, crossectional thickness; CSA, crossectional area; MMI, polar moment of inertia. Values 






Table 4. Differences in femoral µCT phenotypes by lactation at 3-week 
 Wild type DMP1-Sost 
 
non-lactating 
group lactating group  
non-lactating 
group lactating group 
 
 
(n = 5) (n = 5) 
 
(n = 5) (n = 5) 
 
  Mean  SD Mean 
 
SD p-value Mean  SD Mean  SD p-value 
Distal femur 








TV, mm3 3.03  ± 0.15  3.34  ± 0.14  0.01  2.50  ± 0.22  3.22  ± 0.30  <0.001 
BV, mm3 0.63  ± 0.15  0.63  ± 0.19  0.99  0.08  ± 0.05  0.19  ± 0.18  0.25  
BV/TV ,% 20.78  ± 4.30  18.82  ± 5.35  0.54  3.13  ± 1.78  5.43  ± 4.65  0.33  
Tb.Th, µm 68.13  ± 1.95  71.69  ± 2.13  0.03  66.57  ± 4.70  73.31  ± 4.96  0.06  
Tb.N,1/mm 3.05  ± 0.64  2.62  ± 0.72  0.35  0.46  ± 0.25  0.77  ± 0.72  0.40  
Tb.Sp, mm 0.26  ± 0.12  0.27  ± 0.06  0.88  0.68  ± 0.17  0.83  ± 0.29  0.35  
Conn.D,1/mm3 121.78  ± 28.36  102.91  ± 41.83  0.43  12.12  ± 5.35  27.55  ± 20.69  0.15  
Midshaft femur 
              
Cs.Th,mm 0.18  ± 0.01  0.13  ± 0.01  <0.001 0.19  ± 0.01  0.14  ± 0.01  <0.001 
periosteal perimeter[mm] 4.76  ± 0.11  4.73  ± 0.12  0.74  4.72  ± 0.15  4.80  ± 0.20  0.51  
endosteal perimeter[mm] 3.80  ± 0.09  4.09  ± 0.15  0.01  3.67  ± 0.18  4.15  ± 0.19  <0.01 
CSA, mm2 0.79  ± 0.05  0.60  ± 0.03  <0.001 0.81  ± 0.05  0.63  ± 0.07  <0.01 
MMI, mm4 0.34  ± 0.03  0.27  ± 0.02  0.01  0.34  ± 0.04  0.30  ± 0.05  0.16  
Abbreviations: TV, tissue volume; BV, bone volume; BV/TV, percent bone volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, 
trabecular separation; Conn.D,connectivity density; Cs.Th, crossectional thickness; CSA, crossectional area; MMI, polar moment of inertia. Values 






2-2. Serum sclerostin level  
Serum sclerostin level was lower in lactating mice compared to non-lactating 
mice in WT at 1-week lactation and in TG at 3-week lactation (Fig. 6). 
 
Figure 6. Effect of lactation on serum sclerostin 
 
 
2-3. Bone turnover markers 
According to lactation, P1NP was significantly lower in lactating mice in both 
WT and DMP1-Sost mice at 1-week lactation. CTX was not significantly 
different according to lactation at any genotype. At late lactation, P1NP was 
significantly higher in DMP1-Sost mice. CTX was not significantly different as 







Figure 7. Effect of lactation on bone turnover markers 
 
 
2-4. Correlation between parameters during lactation  
During lactation, the correlation of sclerostin with bone turnover markers and 
bone density and quality was analyzed (Table 5). There was a significantly 
negative correlation between P1NP and sclerostin in lactating DMP1-Sost mice, 





Table 5. Correlation between sclerostin and bone turnover markers and measures of bone 
mass and structures in lactating mice 
 Sclerostin 
 WT DMP1-Sost 
 r p r p 
Bone turnover marker     
P1NP -.248 .392 -.591* .026 
CTX-1 0.152  0.605 -.152 .605 
Parameters by DXA      
Spine BMD .638* .014 .373 .189 
Femur BMD .556* .039 .697** .006 
Parameters by micro CT      
Trabecular bone parameters     
Tissue volume [mm3] .091 .803 .267 .488 
Bone volume [mm3] .382 .276 .167 .668 
Percent bone volume [%] .394 .260 .117 .765 
Bone surface [mm2] .418 .229 .317 .406 
Bone surface / volume ratio [BS/BV][1/mm] -.236 .511 .350 .356 
Bone surface density [BS/TV][1/mm] .370 .293 .383 .308 
Trabecular thickness,Tb.Th [mm] .333 .347 -.317 .406 
Trabecular number,Tb.N [1/mm] .370 .293 .317 .406 
Trabecular separation,Tb.Sp [mm] -.224 .533 -.350 .356 
Trabecular pattern factor,Tb.Pf [1/mm] -.309 .385 .483 .187 
Structure model index, SMI -.309 .385 .233 .546 
Connectivity .430 .214 .343 .366 
Connectivity density [1/mm3] .467 .174 .333 .381 
Degree of anisotropy,DA .430 .214 -.083 .831 
Cortical bone parameters     
Crossectional thickness,Cs.Th [mm] .539 .108 .400 .286 
periosteal perimeter [mm] .139 .701 .333 .381 
endosteal perimeter [mm] -.733* .016 .233 .546 
Crossectional area [mm2] .527 .117 .450 .224 
polar moment of inertia,MMI(polar) [mm4] .297 .405 .633 .067 
Eccentricity, Ecc .370 .293 -.494 .177 
Spearman`s correlation coefficients presented. Data are shown as r-values.   
     





3. Effect of duration of lactation  
3-1. Bone density and microarchitectures 
Longer lactation significantly affected more deteriorated femur BMD in both 
type of mice. Difference of spine BMD according to duration of lactation was 
not significant (Fig. 8). Cortical bone compartment in mid-femur was 
significantly lower in both WT and DMP1-Sost mice. In WT, trabecular 
architectures were not different at between 1-week lactation and 3-week 
lactation; however, trabecular thickness significantly higher in DMP1-Sost mice 
at 3-week lactation and other parameters tended to be higher tissue volume, 
bone volume, percent bone volume, trabecular thickness, connectivity density 
compared to the parameters at 1-week lactation (Table 6). Significant loss of 
femoral BMD could be explained by deterioration of cortical parameters (lower 
Cs.Th and CSA) in both genotype mice. Interestingly, trabecular thickness 




Figure 8. Effect of duration of lactation on BMD
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Table 6. Differences in femoral µCT phenotypes by duration of lactation in wild type and DMP1-Sost mice 
 Wild type  DMP1-Sost mice  
 
1-week lactation 3-week lactation  
 
1-week lactation 3-week lactation  
 
 
(n = 5) (n = 5) 
 
(n = 5) (n = 5) 
 
 Mean  SD Mean  SD p-value Mean  SD Mean  SD p-value 
Distal femur 
      
 
      
 
TV, mm3 3.31  ± 0.12  3.34  ± 0.14  0.69  3.07  ± 0.17  3.22  ± 0.30  0.37  
BV, mm3 0.79  ± 0.07  0.63  ± 0.19  0.12  0.09  ± 0.04  0.19  ± 0.18  0.31  
BV/TV ,% 23.82  ± 2.26  18.82  ± 5.35  0.09  3.05  ± 0.97  5.43  ± 4.65  0.30  
Tb.Th, µm 72.78  ± 4.30  71.69  ± 2.13  0.63  60.15  ± 6.40  73.31  ± 4.96  0.01  
Tb.N,1/mm 3.28  ± 0.30  2.62  ± 0.72  0.10  0.51  ± 0.15  0.77  ± 0.72  0.45  
Tb.Sp, mm 0.23  ± 0.02  0.27  ± 0.06  0.19  0.72  ± 0.14  0.83  ± 0.29  0.48  
Conn.D,1/mm3 134.73  ± 24.29  102.91  ± 41.83  0.18  25.50  ± 5.82  27.55  ± 20.69  0.84  
Midshaft femur 
              
Cs.Th,mm 0.15  ± 0.01  0.13  ± 0.01  <0.01 0.16  ± 0.01  0.14  ± 0.01  0.01  
periosteal perimeter[mm] 4.84  ± 0.12  4.73  ± 0.12  0.18  4.90  ± 0.23  4.80  ± 0.20  0.48  
endosteal perimeter[mm] 4.04  ± 0.14  4.09  ± 0.15  0.53  4.01  ± 0.21  4.15  ± 0.19  0.31  
CSA, mm2 0.70  ± 0.04  0.60  ± 0.02  <0.01 0.74  ± 0.07  0.63  ± 0.07  0.04  
MMI, mm4 0.32  ± 0.03  0.27  ± 0.02  0.02  0.35  ± 0.06  0.30  ± 0.05  0.17  
Abbreviations: TV, tissue volume; BV, bone volume; BV/TV, percent bone volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular 




3-2. Serum sclerostin level  
Serum sclerostin level was significantly lower at 3-week of lactation in 




Figure 9. Effect of duration of lactation on serum sclerostin 
 
 
3-3. Bone turnover markers 
P1NP level was not different according the length of lactation in wild type; 
however, the average of P1NP level of DMP1-Sost mice at 3 week lactation 
period was significantly higher compared to level of mice at 1-week of lactation. 
This result could be explained by the significant lower level of sclerostin at 3 
week in lactating DMP1-Sost than the level at 1week of lactation. CTX level 
was not significantly different between two times in both WT and DMP1-Sost 




Figure 10. Effect of duration of lactation on bone turnover markers 
 
4. Effect of weaning  
4-1. Bone density and microarchitectures 
After stopping lactation, femur BMD in wild type and DMP1-Sost mice were 
significantly higher at 2 weeks after weaning in wild type compared to 3-week 
lactation; however, femur BMD in both types of mice did reach to the level of 
age-matched non-lactating control mice (Fig. 11).  
 
 
Figure 11. Effect of weaning (3 week lactation vs. weaning group) 
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In contrast, spine BMD of WT lactating mice did reach to that of the 
non-lactating control mice after weaning, average spine BMD in DMP1-Sost 
did not increase significantly resulting to failure to reach to BMD of 
non-lactating control (Fig. 12). 
 
 
Figure 12. Effect of weaning (age-matched non-lactating vs. weaning)  
 
We further investigated bone quality of distal femur by microCT. In WT, higher 
cross-sectional thickness, cross-sectional area, and higher partial moment of 
inertia in cortical bone compartment were observed at 2-week after weaning 
compared to 3-week lactation (Table 7); however, cross-sectional thickness at 
the mid-shaft femur remained below this parameter in age-matched 
non-lactating mice. Trabecular compartment in the distal femur of WT did not 
show the significant difference compared to non-lactating WT control mice 
showing the restoration of trabecular bone. In DMP1-Sost weaned mice, 
cortical bone compartment also remained below the compartment of 
non-lactating DMP1-Sost mice (table 8). Between WT and DMP1-Sost weaned 
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mice, only the difference of trabecular compartment was observed (lower bone 
volume (BV), percent bone volume (BV/TV), trabecular number (Tb.N), and 
higher trabecular separation (Tb.Sp) and connectivity density (Conn.D).  
 
4-2. Serum sclerostin level  
At 2 weeks after weaning, mean of sclerostin level was lower in wild type, in 
contrast, higher in DMP1-Sost; however there was no significance between 
lactating and weaned mice (Fig. 13). 
 
 
Figure 13. Effect of weaning on serum sclerostin 
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Table 7. Differences in femoral µCT phenotypes between 3-week lactation and weaning  
 Wild type DMP1-Sost 
 
3-week lactation  Weaning 
 
3-week lactation  Weaning 
 
 
(n = 5) (n = 5) 
 
(n = 5) (n = 5) 
 
  Mean  SD Mean 
 
SD p-value Mean  SD Mean  SD p-value 
Distal femur 








TV, mm3 3.34  ± 0.14  2.96  ± 0.26  0.02  3.22  ± 0.30  2.86  ± 0.27  0.08  
BV, mm3 0.63  ± 0.19  0.60  ± 0.17  0.76  0.19  ± 0.18  0.13  ± 0.15  0.60  
BV/TV ,% 18.82  ± 5.35  20.04  ± 5.18  0.72  5.43  ± 4.65  4.22  ± 4.56  0.69  
Tb.Th, µm 71.69  ± 2.13  72.12  ± 5.13  0.87  73.31  ± 4.96  68.69  ± 3.23  0.12  
Tb.N,1/mm 2.62  ± 0.72  2.76  ± 0.59  0.75  0.77  ± 0.72  0.62  ± 0.68  0.74  
Tb.Sp, mm 0.27  ± 0.06  0.24  ± 0.03  0.42  0.83  ± 0.29  0.66  ± 0.28  0.39  
Conn.D,1/mm3 102.91  ± 41.83  111.32  ± 50.77  0.18  27.55  ± 20.69  15.10  ± 19.70  0.36  
Midshaft femur 
    
 
      
 
  
Cs.Th,mm 0.13  ± 0.01  0.17  ± 0.02  <0.01 0.14  ± 0.01  0.15  ± 0.01  0.05  
periosteal perimeter[mm] 4.73  ± 0.12  4.76  ± 0.09  0.67  4.80  ± 0.20  4.79  ± 0.12  0.96  
endosteal perimeter[mm] 4.09  ± 0.15  3.90  ± 0.09  0.04  4.15  ± 0.19  3.98  ± 0.15  0.16  
CSA, mm2 0.60  ± 0.02  0.74  ± 0.07  <0.01 0.63  ± 0.07  0.69  ± 0.04  0.17  
MMI, mm4 0.27  ± 0.02  0.32  ± 0.04  0.02  0.30  ± 0.05  0.31  ± 0.03  0.52  
Abbreviations: TV, tissue volume; BV, bone volume; BV/TV, percent bone volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, 
trabecular separation; Conn.D,connectivity density; Cs.Th, crossectional thickness; CSA, crossectional area; MMI, polar moment of inertia. Values are 
means ± standard deviation (SD). 
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Table 8. Microstructures in µCT at 2-week time after weaning compared to age-matched non-lactating mice in both genotype 
 








(n = 5) (n = 5) 
 
(n = 5) (n = 5) 
 










TV, mm3 2.68  ± 0.20  2.96  ± 0.26  
 
2.71  ± 0.16  2.86  ± 0.27  
 
BV, mm3 0.44  ± 0.12  0.60  ± 0.17  
 
0.14  ± 0.09  0.13  ± 0.15  *# 
BV/TV ,% 16.05  ± 3.46  20.04  ± 5.18  
 
5.30  ± 3.24  4.22  ± 4.56  *# 
Tb.Th, µm 70.79  ± 5.10  72.12  ± 5.13  
 
69.41  ± 3.87  68.69  ± 3.23  
 
Tb.N,1/mm 2.27  ± 0.44  2.76  ± 0.59  
 
0.77  ± 0.46  0.62  ± 0.68  *# 
Tb.Sp, mm 0.26  ± 0.03  0.24  ± 0.03  
 
0.68  ± 0.24  0.66  ± 0.28  *# 
Conn.D,1/mm3 66.44  ± 21.92  111.32  ± 50.77  
 











Cs.Th,mm 0.19  ± 0.00  0.17  ± 0.02  * 0.19  ± 0.01  0.15  ± 0.01  *$ 
periosteal perimeter[mm] 4.74  ± 0.20  4.76  ± 0.09  
 
4.73  ± 0.14  4.79  ± 0.12  
 
endosteal perimeter[mm] 3.70  ± 0.11  3.90  ± 0.09  * 3.72  ± 0.15  3.98  ± 0.15  *$ 
CSA, mm2 0.82  ± 0.05  0.74  ± 0.07  
 
0.80  ± 0.04  0.69  ± 0.04  *$ 
MMI, mm4 0.35  ± 0.05  0.32  ± 0.04    0.34  ± 0.03  0.31  ± 0.03    
Abbreviations: TV, tissue volume; BV, bone volume; BV/TV, percent bone volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, 
trabecular separation; Conn.D,connectivity density; Cs.Th, crossectional thickness; CSA, crossectional area; MMI, polar moment of inertia.  
Values are means ± standard deviation (SD), *, p <0.05 (vs. wild type control), #, p <0.05 (vs. wild type wean), $, p <0.05 (vs. DMP1-Sost control). 
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4-3. Bone turnover markers 
After stopping lactation, P1NP levels were significant lower at 2 weeks after 
weaning compared to the 3-week lactating point; however, CTX did not show 
significant difference between two time points (Fig. 14). 
 
Figure 14. Effect of weaning on bone turnover markers 
 
5. Effect of genotype  
5-1. Bone density and microarchitectures 
Spine bone mineral density (BMD) was significantly lower in DMP1-Sost 
mice, osteocyte-specific sclerostin overexpressed mice, than those in wild type 
mice compared by genotype (Fig. 15). 
 
Figure 15. Effect of genotype on BMD 
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However, BMD of the femur between WT and TG were not significantly 
different. Despite of no difference in femur BMD in DXA, there were 
significantly different in microarchitectures of trabecular bone in distal femur 
between WT and TG on microCT analysis. MicroCT measurements of the 
lumbar vertebrae of TG mice have marked reductions in tissue volume (TV), 
bone volume (BV), trabecular thickness (Tb. Th), trabecular number (Tb. N), 
and connectivity of density, increased trabecular separation (Tb.Sp). Cortical 
bone parameters in mid-shaft were not significantly different (Table 9).  
 
Table 9. Microstructures in femoral µCT phenotypes by genotype   
 
Wild type DMP1-Sost 
 
 
(n = 5) (n = 5) 
 
 Mean  SD Mean  SD p-value 
Distal femur 
      
 
TV, mm3 3.05  ± 0.28  2.88  ± 0.34  0.04  
BV, mm3 0.62  ± 0.19  0.14  ± 0.12  <0.001 
BV/TV ,% 20.24  ± 5.31  4.56  ± 3.40  <0.001 
Tb.Th, mm 0.07  ± 0.00  0.07  ± 0.01  <0.001 
Tb.N,1/mm 2.82  ± 0.71  0.70  ± 0.53  <0.001 
Tb.Sp, mm 0.26  ± 0.08  0.70  ± 0.22  <0.001 
Conn.D,1/mm3 110.78  ± 42.68  25.06  ± 21.91  <0.001 
Midshaft femur 
       
Cs.Th,mm 0.17  ± 0.02  0.17  ± 0.02  0.89  
periosteal perimeter[mm] 4.78  ± 0.14  4.79  ± 0.16  0.91  
endosteal perimeter[mm] 3.89  ± 0.18  3.88  ± 0.23  0.78  
CSA, mm2 0.75  ± 0.09  0.75  ± 0.08  0.97  
MMI, mm4 0.33  ± 0.05  0.33  ± 0.05  0.81  
Abbreviations: TV,tissue volume; BV, bone volume; BV/TV, percent bone volume;Tb.Th, 
trabecular thickness; Tb.N, trabecular number;Tb.Sp, trabecular separation; Conn.D,connectivity 
density; Cs.Th, crossectional thickness; CSA, crossectional area; MMI, polar moment of inertia.  





5-2. serum sclerostin level  
Serum sclerostin level did not show any significant difference by genotype at 
each matched status according to age, lactation or weaning (Table 10).  
 
Table 10. Serum sclerostin level at each time  
  Sclerostin level (pg/mL)  
  WT TG 
1-week  
  
non-lactating 274.42 ± 31.29 243.47 ± 23.91 
lactating 202.67 ± 61.28 229.69 ± 45.02 
3-week  
      
non-lactating 240.04 ± 45.65 231.94 ± 57.54 
lactating 174.09 ± 65.81 145.05 ± 18.98 
2 week after weaning 
     
non-lactating 214.26 ± 34.54 202.24 ± 29.40 
lactating 157.85 ± 34.14 163.21 ± 16.11 
 
 
5-3. Bone turnover markers 
P1NP, bone formation marker, was significantly lower in DMP1-Sost mice 
compared to wild type mice irrespective of lactation at 1-week lactation time; 
however, after 3- week lactation, serum sclerostin level was significantly lower in 
DMP1-Sost mice in non-lactation status. Average of CTX were slightly higher in 




Table 11. Serum bone turnover markers at each time  
  P1NP (ng/mL)   CTX (ng/ml) 
  WT TG   WT TG 
1-week  
         
non-lactating 90.84 ± 5.58 75.08 ± 9.47 * 38.83 ± 10.28 39.66 ± 19.02 
lactating 78.30 ± 11.68 45.45 ± 6.15 * 60.84 ± 44.76 61.19 ± 29.82 
3-week  
             
non-lactating 61.40 ± 10.92 48.76 ± 4.61 * 43.96 ± 25.95 46.85 ± 25.25 
lactating 75.61 ± 24.94 78.16 ± 9.44 
 
47.17 ± 28.31 51.99 ± 17.13 
2 week after weaning 
            
non-lactating 44.36 ± 8.43 36.60 ± 5.39 
 
29.00 ± 15.34 30.54 ± 16.80 
lactating 52.85 ± 8.75 55.12 ± 11.00   23.74 ± 13.00 34.78 ± 15.31 
P1NP, the amino-terminal propeptide of type 1 procollagen; CTX, cross-linked C-telopeptide; 
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Figure 16. Comparisons in spine and femur BMD during lactation and weaning period. Lactating mice (■) were 
compared to age-matched non-lactating control mice (□). A, spine BMD were compared to age-matched control; p < 0.05; * 
lactating vs age-matched non-lactating group in the same genotype; ** TG vs age-matched WT in non-lactating group, § 















In the present study, we found SOSTDC1, LRP5, LRP6 pathogenic variants 
related Wnt signaling pathway in pregnancy and lactation associated 
osteoporosis (PLO) patients. We also revealed sclerostin, Wnt signaling 
inhibitor and secreted by osteocyte, has important influence on controlling bone 
mineral metabolism during lactation and weaning.   
Canonical Wnt signaling is initiated by binding of Wnt ligands to dual 
receptor complex comprised of frizzled and either LRP5/6, resulting to bone 
formation31. Sclerostin, secreted primarily from osteocytes, inhibits Wnt 
signaling by binding to LRP5 and the related LRP4 and LRP6 receptors21,32. In 
our whole exome sequencing study, pathogenic variants related Wnt pathway 
were detected in 7/12 cases. Especially, observed variants of LRP5 or LRP6 
encode the extracellular domain of LRP5/6, important for sclerostin as a ligand 
to bind the receptor and regulate the bone formation30,33. These findings could 
infer that mutations of SOSTDC1, LRP5, LRP6 genes would be one of genetic 
risk factors for PLO in women in pregnancy. In addition, HGMD based 
candidate gene analysis showed all 12 patients have common variant, CALCR 
p.Pro447Leu and C17orf53 p.Thr126Pro26 related calcium sensing receptor 
suggesting calcium metabolism and bone mineral density, respectively. 
TNFRSF11A, TNFRSF11B were also nonsynonymous SNPs, associated with the 
regulation to activate osteoclast, which is important to maintain the balance of 
bone remodeling. In addition these nonsynonymous SNPs, PR domain zinc 
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finger protein 2 (PRDM2), interacting with estrogen receptor alpha suggests 
bone resorption and mineral metabolism are also importantly involved in PLO 
women.  
With association of sclerostin-Wnt signaling to PLO patients, to further 
investigate sclerotin-Wnt signaling related bone deterioration during lactation 
and weaning, we evaluated and compared bone density and microarchitectures 
among non-lactating and lactating mice in wild type and osteocyte-specific 
sclerostin overexpressed transgenic mice (DMP1-Sost mice). By genotype, only 
trabecular-dominant lumbar spine and trabecular compartment of distal femur 
was affected suggesting the osteocyte-specific sclerostin overexpression in 
DMP1-Sost mice deteriorates trabecular bone dominantly. This bone phenotype 
of DMP1-Sost mice was consistent the previous study34.  
Lactation dramatically increases skeletal bone turnover to provide calcium 
to pups through milk. Increased bone turnover uncoupled remodeling results to 
bone resorption. Previous studies revealed that lactating mice resorb bone 
mineral primarily from trabecular-rich vertebrae, to a lesser extent from 
trabecular bone of the femora and tibiae, and much less from purely cortical 
bones 19,35-38. In our study, both lower spine and femur aBMD by DXA and 
deteriorated cortical compartments and bone strength (polar moment of inertia) 
in distal femur revealed active bone resorption in both trabecular and cortical 
bones of wild type and DMP1-Sost mice during lactation. In addition, 
significant reduction of cortical site in lactating mice compared to age-matched 
non-lactating mice could be explained by osteocytic osteolysis as well as 
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osteoclast-mediated bone resorption is important in lactating mice. Even though 
osteocyte-specific sclerostin overexpression deteriorated only trabecular 
compartment in distal femur in mice, lactation resulted to trabecular and cortical 
compartment bone in both WT and DMP1-Sost mice. This result could be 
explained by that lactation is strong stimuli to deteriorate bone mineral 
metabolism. Serum sclerostin level, which was not affected by genotype, was 
suppressed in lactating status compared to non-lactating status, suggesting 
osteocytes work by controlling sclerostin in response to bone loss during 
lactation35.  
Depending on duration of lactation, longer lactation more deteriorated 
mid-shaft femoral architectures in both genotype. At 3-week lactation in 
DMP1-Sost, serum sclerostin was significantly lower and bone formation 
marker, P1NP was significantly higher than the level at 1-week lactation or 
age-matched non-lactating mice. Endogenous sclerostin would be suppressed 
more significantly in DMP1-Sost mice by compensatory response to prolonged 
lactation resulting to devastating bone loss, and subsequent overexpression of 
osteocyte-specific sclerostin39. In microCT, increased bone formation in 
DMP1-Sost at 3-week lactation contributed higher trabecular microarchitecture 
in distal femur despite of more reduction in femur BMD at 3-week lactation. 
This finding could expect that decreased sclerostin could activate Wnt signaling 




Weaning also leads to activation of bone formation, a rapid process of 
remineralization to the pre-pregnancy level in the maternal skeleton1,5,6,20,41,42. 
Bone turnover increases and is uncoupled in the opposite direction from 
lactation, finally to regain bone mass. Previous studies revealed that C57BL/6 
mice regain their BMC in whole body, lumbar spine within 14 days of 
weaning20. Consistent to study of Liu et. al38, trabecular-dominant lumbar spine 
BMD and trabecular microarchitectures at distal femur recovered to the level of 
non-lactating mice in WT. However, deterioration of trabecular architectures in 
weaned DMP1-Sost mice compared to weaned WT mice. At 2-week after 
weaning, incomplete recovery of trabecular microarchitectures at distal femur in 
DMP1-Sost mice would also explain that sclerostin would affect bone formation, 
especially in trabecular compartment during weaning period. Lastly, in 
correlation analysis, serum sclerostin level is positively related with spine and 
both BMD in wild type mice consistent to results of healthy human studies43. In 
DMP1-Sost mice, detection of serum sclerostin could be differed by amount of 
human Sost-gene expression resulting to different serum sclerostin level.  
In our PLO women, all women had vertebral fracture. The phenotype of 
vertebral compression fractures could be inferred to severe bone loss during 
pregnancy and lactation, or failure of recovery after weaning. In the light of our 
animal study, failure of osteocyte-associated compensatory response for 
devastating bone loss due to lactation in regulating sclerostin level related with 
Wnt signaling, could result to pregnancy and lactation associated osteoporosis.  
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Our study has several limitations. For genetic analysis, our cases were only 
twelve. Whole exome-sequencing has limitations itself because of lack of 
sequence coverage of the variants, variant calling issues, possibility to miss the 
cause of the disease if located outside the coding sequences44. We could not 
validate the genetic mutation detected in our women by functional study. Our 
animal study is limited by a cross-sectional study design. We could not measure 
parameters of the mice during the period from pregnancy to weaning 
longitudinally. Lastly, we could not measure milk production, dietary calcium 
intake. Number of pups, change of weight during from pregnancy to weaning 
was not adjusted to analyze the difference of BMD.  
Despite of several limitations, to our knowledge, this is the first study that 
bone contents and density by DXA and microarchitectures by micro CT 
together with serum sclerostin and bone turnover markers have been evaluated 
in DMP1-Sost transgenic mice during lactation and weaning compared to WT 
mice. In addition, we also revealed the novel candidate genes, LRP6 and 
SOSTDC1 related to Wnt signaling suggesting that sclerostin-Wnt signaling 
would be important to control bone formation to adapt bone and mineral 










Whole-exome sequencing allowed for confirming the involvement Wnt 
signaling related sclerostin and LRP5/6 in PLO women with vertebral 
compression fractures. Osteocyte-specific sclerostin-overexpressed DMP1-sost 
mice study also revealed that sclerostin controlled by osteocyte would be 
important to adapt bone mineral metabolism to bone loss during lactation and 
activate Wnt signaling for bone formation to achieve the recovery to 
pre-pregnancy level during weaning. More functional studies of genes 
discovered by our study would be needed. However, these findings would be 
important clues to identify vulnerability to pregnancy and lactation associated 
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ABSTRACT (IN KOREAN) 
 
골세포 특이 스클레로스틴 유전자 변형 마우스 모델에서 수유 및 
이유에 따른 골대사 및 미세구조 변화 
 
< 지도교수   이 유 미 > 
 
연세대학교 대학원 의학과 
 
이 수 진  
 
 
출산 후 수유시에는 아이에게 칼슘 및 무기질을 전달하기 위해 
모체에서는 뼈 소실이 일어난다. 하지만, 수유를 중단한 후에는 빠른 
속도로 재무기질화가 일어나게 된다. SOST 유전자로 발현되는 
스클레로스틴 (sclerostin) 은 골세포 (osteocyte) 에서 주로 
분비되는데, LRP5/6 의 세포외 도메인에 결합하여 윈트 신호를 
억제함으로서 골재형성을 조절하는 중요한 역할을 한다. 하지만, 
스클레로스틴과 윈트 신호가 수유와 이유기간 동안 골재형성을 
조절하는데 어떤 역할을 하는지는 아직 연구된 바가 없다.  
이번 연구에서, 저자들은 드물게 발생하는 다발성 척추 골절이 있는 
임신 및 수유 관련 골다공증은 윈트 신호경로의 돌연변이와 관련이 
있을 것이며, 윈트 신호와 관련된 스클레로스틴이 수유와 이유기간 
동안 골대사 및 미세구조에 영향을 미칠 것이다라고 가설을 세웠다.   
저자들은 전장 엑솜 분석기법을 이용하여 다발성 척추 골절이 있는 
임신 및 수유 관련 골다공증 환자에서 유전자 변이와 임신 및 수유 
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관련 골다공증과의 관련성을 알아보고자 하였으며, 스클레로스틴의 
이중에너지 X 선 흡수계측법과 미세컴퓨터단층촬영시스템을 이용하여 
정상 마우스 및 골세포 특이 스클레로스틴 과발현 유전자 도입 
(DMP1-Sost) 마우스의 골량 및 미세구조에 미치는 영향을 확인하고자 
하였다. 결과를 보면, 전장 엑솜 분석에서는 다발성 척추 골절이 있는 
임신 및 수유 관련 골다공증 환자 12 명 중 8 명에서 LRP5/6 에서 
스클레로스틴이나 윈트 신호 수용체 작용제가 결합하는 세포외 
도메인을 코딩하는 유전자에 돌연변이가 있었다. 동물 연구 결과에서는 
수유는 1 주 및 3 주 수유했을 때 척추 및 대퇴부 골밀도를 유의하게 
감소시켰고, 특히, 대퇴간부의 피질골 미세구조(단면적 및 단면 두께)가 
손상되었다. 이유 후 2 주 후에는 결과는 대퇴부 골밀도 및 대퇴간부 
피질골 미세구조는 정상 및 DMP1-Sost 마우스에서 모두 회복이 되지 
않았다. 하지만, 정상 마우스에서는 척추 골밀도 및 대퇴골 원위부는 
회복이 된 반면에 DMP1-Sost 는 두 부위 모두 회복되지 않은 결과로 
미루어보다 이는 스클레로스틴 과발현이 특히 해면골이 주로 차지하는 
뼈부분에 영향을 끼치는 것으로 사료된다. 요약하자면, 윈트 시그널 
억제자인 스클레로스틴이 결합하는 LRP5/6 세포외 도메인의 유전자 
돌연변이가 수유 및 이유 중 대한 모체의 골대사 적응기전의 실패로 
인한 임신 및 수유 관련 골다공증 질병을 일으키는 유전적 위험 요인 
중의 하나일 수 있겠으며, 골세포에 의한 스클레로스틴의 레벨 조절은 
수유 중 골소실을 보상하고, 이유 후에 골밀도 회복을 달성하는데 
중요한 역할을 할 것이다.  
------------------------------------------------------------------------------------------------ 
핵심되는 말: 윈트 신호 경로, DMP1-hSOST 유전자 도입 마우스, 
스클레로스틴, LRP5/6, 전장 엑솜 분석, 임신 수유 관련 골다공증  
